Roche’s Skyscraper looks on shaky foundations
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.
Novartis drops out of KRAS
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
A second-line degrader battle beckons
Readouts for Lilly and Pfizer/Arvinas loom, but many SERD hopefuls are now focused on earlier-stage breast cancer.
Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
Scancell faces its big decision
Data in the coming months will inform which immunotherapy the UK company takes into pivotal development.
